Subscribe to AI For Pharma Growth’s news feed.
Click on “Follow” and decide if you want to get news from AI For Pharma Growth via RSS, as email newsletter, via mobile or on your personal news page.
Subscription to AI For Pharma Growth comes without risk as you can unsubscribe instantly at any time.
You can also filter the feed to your needs via topics and keywords so that you only receive the news from AI For Pharma Growth which you are really interested in. Click on the blue “Filter” button below to get started.
Website title: AI For Pharma Growth
Is this your feed? Claim it!
In this solo episode of AI For Pharma Growth, Dr Andree Bates explores what health technology assessment bodies now expect when AI is used to generate, analyse or support evidence.
The episode looks at the emerging principles from NICE in England, CDA-AMC in Canada and the EU Joint Clinical Assessment framework. While none of these bodies has banned AI, Andree explains ...
In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Mattia Marco Caruson, co-founder and CEO of mama health, about how generative AI is changing the way pharma understands the patient journey.
Mattia explains why traditional methods such as surveys, focus groups and clinician interviews often capture only fragments of what patients actually experience. ...
In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Dr. Kurt Rohloff, co-founder and CEO of Duality Technologies, about how privacy-enhancing technologies could unlock data collaboration without forcing organisations to give up control of sensitive information.
Kurt explains how technologies such as fully homomorphic encryption and federated learning al...
In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Clara Bernardes, co-founder and CSO of Biorce, about how AI can accelerate clinical development without sacrificing compliance or scientific rigour.
Biorce was born from a deeply personal experience. After Clara's father-in-law received a terminal melanoma diagnosis, access to a clinical trial through ...